Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

24P - TPD54 as a candidate biomarker for distant metastasis prediction in non-endemic nasopharyngeal carcinoma: Label-free quantitative proteomics results

Date

21 Mar 2023

Session

Poster display session

Presenters

Eduardo Netto

Citation

Annals of Oncology (2023) 8 (1suppl_3): 101023-101023. 10.1016/esmoop/esmoop101023

Authors

E. Netto1, H.M. Santos2, L. Carvalho2, S. Esteves3, F. Silva4, M. Rito5, J. Cabeçadas5

Author affiliations

  • 1 Radiation Oncology, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E. (IPO Lisboa), 1099-023 - Lisbon/PT
  • 2 Chemistry Department, BIOSCOPE Research Group, LAQV-REQUIMTE, Chemistry Department, NOVA School of Science and Technology, FCT NOVA, Universidade NOVA de Lisboa, 2829-516 - Caparica/PT
  • 3 Clinical Research Unit, Instituto Portuguès de Oncologia de Lisboa Francisco Gentil E.P.E. (IPO Lisboa), 1099-023 - Lisbon/PT
  • 4 Pathology Department, NOVA Medical School - Faculdade de Ciencias Medicas, 1169-056 - Lisbon/PT
  • 5 Pathology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E. (IPO Lisboa), 1099-023 - Lisbon/PT

Resources

This content is available to ESMO members and event participants.

Abstract 24P

Background

Nasopharyngeal carcinoma (NPC) has excellent local control in the IMRT era. Nevertheless, distant metastases are the leading cause of death and challenge the scientific community. We report our results of mass-spectrometry based research for biomarkers to predict metastasis.

Methods

We retrieved clinical image and outcomes of biopsy-proven untreated NPC patients between 2009 and 2013 treated with IMRT with or without concurrent chemotherapy. One slice of 10um of formalin-fixed paraffin-embedded sample from each patient was submitted to label-free quantitative proteomics analysis. Label-free quantification was carried out using MaxQuant software V1.6.0.16. Database searches were performed using the Andromeda search engine with the UniProt-SwissProt Human Uniprot Proteome database as a reference and a contaminants database of common contaminants. Clinical results of distant metastasis outcomes were compared to proteomic analysis.

Results

We retrieved 82 patients, from which 18 developed distant metastases (M1). A pool of 25 proteins significantly up-regulated and 303 proteins down-regulated in M1 patients. Among differentially expressed proteins, tumor protein D54 (TPD54) had the highest difference in M1 patients (-Log(P-value) = 6,223915243; Difference = -0,466002574; Gene TPD52L2; p<0.01). Other proteins are CALM-1, SGT1, immunoglobulin, and ribosomal proteins (p<0.01). Among signalling pathways found, Ras-related protein Rab-33A (gene RAB33A) was significantly up-regulated in M1 patients (p<0.01).

Conclusions

We report a tumour profiling of 25 proteins up-regulated in metastatic NPC from a European cohort. TPD54 was identified as a potential biomarker candidate for metastasis prediction, and Ras GTPase signaling pathway was also up-regulated in metastatic patients.

Clinical trial identification

Editorial acknowledgement

Prof. J.L. Capelo-Martínez for his assistance in this study.

Legal entity responsible for the study

The authors.

Funding

IPOLFG Research Fund [grant 2015/UIC901].

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.